XinYue Biologics Completes Series A+ Strategic Financing to Advance DEL+AI Drug Discovery Platform

Recently, NewDEL Biotech announced the completion of a strategic A+ round investment led by XtalPi-P (2228.HK), a global leader in AI + automation technology platforms. NewDEL Biotech's DNA Encoded Library (DEL) technology will be deeply integrated with XtalPi’s AI platform technology to accelerate the development and commercialization of innovative drug pipelines. This round of financing will further enhance the deep development of NewDEL Biotech's DEL+AI technology platform and innovative pipeline layout, improving the efficiency and success rate of early-stage drug discovery.

NewDEL Biotech has deep technical accumulation and rich practical experience in DNA-encoded library (DEL) technology. Its DEL technology can rapidly generate a vast number of compound molecules and achieve efficient screening through a unique encoding method. XtalPi is a pioneer and leading company in the field of AI-driven drug discovery, and its AI drug discovery platform integrates high-precision quantum physics, computational chemistry algorithms, and more than hundreds of AI models. This allows for the efficient exploration of ultra-large-scale drug chemical space, designing and optimizing molecular structures that balance innovation with drug-like properties, thereby accelerating the clinical translation of innovative pipelines.

Public information shows that Shenzhen NewDEL Biotech Co., Ltd. ("NewDEL Biotech" for short) is a clinical-stage innovative drug R&D company incubated and controlled by the Guangdong Small Molecule Innovative Drug Innovation Center. Established in April 2021, the company focuses on DNA-Encoded Library (DEL) technology as its core, building multiple 0-1 drug discovery technology platforms (DEL+X), and owns a compound library with over 100 billion physical molecules. Its unique DEL live-cell screening technology can effectively screen difficult-to-express and purify targets, greatly expanding the range of targets and hit rates in new drug screening. With the starting point of "empowering new drug development with distinctive technologies and making affordable quality medicines for the people," NewDEL Biotech is committed to becoming an internationally leading and uniquely distinctive new drug R&D biopharmaceutical company.